Figure 4
Figure 4. Short TSLPR CAR T cells demonstrate activity over a broad dose range and mediate durable eradication of TSLPRhi ALL at high leukemic burden. (A) Dose titration of short TSLPR CAR T cells given on day 3 after high-dose REH TSLPR ALL injection (5 × 106 cells/mouse). ACT, adoptive cell transfer. (B) Survival plot of mice treated in Figure 4A. (C) Flow cytometry of peripheral blood for the presence of CD45+ leukemia cells at day 12 after injection. (D) Quantitation of bioluminescence in mice treated in Figure 4A.

Short TSLPR CAR T cells demonstrate activity over a broad dose range and mediate durable eradication of TSLPRhi ALL at high leukemic burden. (A) Dose titration of short TSLPR CAR T cells given on day 3 after high-dose REH TSLPR ALL injection (5 × 106 cells/mouse). ACT, adoptive cell transfer. (B) Survival plot of mice treated in Figure 4A. (C) Flow cytometry of peripheral blood for the presence of CD45+ leukemia cells at day 12 after injection. (D) Quantitation of bioluminescence in mice treated in Figure 4A.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal